Nanofloxacin malate, a class 1 new drug of Zhejiang medicine, is expected to obtain production approval within half a year

According to the information of the State Food and Drug Administration (CFDA), a class of new drug, nynorfloxacin malate and its capsule preparation, which has attracted much market attention, have entered the stage of waiting for on-site inspection This also means that the drug has passed the technical review of new drugs and is expected to obtain production approval within half a year In September last year, ninofloxacin passed the expert review The company's personnel confirmed to the big smart news agency that the review feedback was optimistic and the important obstacles to approval had been removed Nanofloxacin is a new type of fluoroquinolones free drug and a high-end product of quinolones It has attracted market attention since its application It is generally believed in the industry that ninofloxacin will form a benign complementary advantage with the existing quinolones and antibiotic resistant products of Zhejiang Pharmaceutical, enrich the company's high-end antibiotic product group, improve and enrich the preparation varieties, and improve the current predicament of the decline in API revenue At present, Zhejiang medicine is mainly engaged in API business and preparation business The 2014 China Daily has disclosed that the API business decreased by 11% year-on-year, while the preparation business increased by 12% year-on-year, and the main business proportion gradually increased According to the latest announcement of Zhejiang medicine, due to a significant decline in the sales price of the leading product VE in the fourth quarter of last year, the net profit in 2014 is expected to decrease by 55% to 75% year on year.